5.535  0.025 (0.45%)		11-14 13:20
Open: 5.42 High: 5.535 Volume: 9,598		Pre. Close: 5.51 Low: 5.42 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	10.26	1-year :	12.99
Resists	First :	8.78	Second :	11.13
Pivot price	5.72
Supports	First :	5	Second :	4.15
MAs	MA(5) :	5.59	MA(20) :	5.88
	MA(100) :	6.5	MA(250) :	21.73
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	26.9	D(3) :	30
RSI	RSI(14): 43.4
52-week	High :	127.71	Low :	4.28

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ELAB ] has closed above bottom band by 18.5%. Bollinger Bands are 63.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	5.98 - 6.01	6.01 - 6.04
Low:	5.43 - 5.46	5.46 - 5.5
Close:	5.45 - 5.51	5.51 - 5.56

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Fri, 14 Nov 2025
PMGC Holdings Inc. SEC 10-Q Report - TradingView

Fri, 31 Oct 2025
PMGC Holdings’ Subsidiary Achieves ITAR Registration - The Globe and Mail

Mon, 20 Oct 2025
PMGC Holdings Inc. Announces Over $711,000.00 in Sales - GlobeNewswire

Mon, 20 Oct 2025
Over $711K Sales Backlog — PMGC's AGA Precision Expands Capabilities, Bids >$700K, Adds CNCs - Stock Titan

Tue, 14 Oct 2025
PMGC Holdings Stock Jumps 230% Premarket, Grabs Retail Eyeballs - MSN

Tue, 14 Oct 2025
ELAB Stock: Will The Surge Continue? - StocksToTrade

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	27.2 (%)
Held by Institutions	2.2 (%)
Shares Short	427 (K)
Shares Short P.Month	18 (K)

EPS	116.66
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	21.43
Profit Margin	0 %
Operating Margin	708.7 %
Return on Assets (ttm)	-37.2 %
Return on Equity (ttm)	-87 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.6
Sales Per Share	-0.82
EBITDA (p.s.)	-5.76
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	0.04
PEG Ratio	0
Price to Book value	0.25
Price to Sales	-6.71
Price to Cash Flow	-0.8

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.